Exelixis Inc. [NASDAQ: EXEL] gained 3.47% or 0.69 points to close at $20.56 with a heavy trading volume of 3335460 shares. The company report on December 7, 2020 that Exelixis In-Licenses Aurigene’s Novel CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Clinical Trial in Advanced Solid Tumors.
– Phase 1 clinical trial expected to begin in Q1 2021 –.
– Under the terms of the companies’ agreement, Exelixis will make an option exercise payment of $12 million to Aurigene –.
It opened the trading session at $20.09, the shares rose to $21.06 and dropped to $20.05, the range by which the price of stock traded the whole day. The daily chart for EXEL points out that the company has recorded -12.21% loss over the past six months. However, it is still -50.4% lower than its most recent low trading price.
If we look at the average trading volume of 2.15M shares, EXEL reached to a volume of 3335460 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Exelixis Inc. [EXEL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EXEL shares is $30.85 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EXEL stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Barclays have made an estimate for Exelixis Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 04, 2020. While these analysts kept the previous recommendation, SunTrust raised their target price to Buy. The new note on the price target was released on January 13, 2020, representing the official price target for Exelixis Inc. stock. Previously, the target price had yet another raise to $22, while BofA/Merrill analysts kept a Buy rating on EXEL stock.
The Average True Range (ATR) for Exelixis Inc. is set at 0.79, with the Price to Sales ratio for EXEL stock in the period of the last 12 months amounting to 6.46. The Price to Book ratio for the last quarter was 3.43, with the Price to Cash per share for the same quarter was set at 3.95. Price to Free Cash Flow for EXEL in the course of the last twelve months was 19.93 with Quick ratio for the last quarter at 6.90.
Trading performance analysis for EXEL stock
Exelixis Inc. [EXEL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.07. With this latest performance, EXEL shares gained by 1.58% in over the last four-week period, additionally sinking by -12.21% over the last 6 months – not to mention a rise of 15.38% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EXEL stock in for the last two-week period is set at 56.37, with the RSI for the last a single of trading hit 67.32, and the three-weeks RSI is set at 52.15 for Exelixis Inc. [EXEL]. The present Moving Average for the last 50 days of trading for this stock 20.97, while it was recorded at 19.53 for the last single week of trading, and 22.02 for the last 200 days.
Exelixis Inc. [EXEL]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Exelixis Inc. [EXEL] shares currently have an operating margin of +38.18 and a Gross Margin at +96.58. Exelixis Inc.’s Net Margin is presently recorded at +33.17.
Return on Total Capital for EXEL is now 24.31, given the latest momentum, and Return on Invested Capital for the company is 21.16. Return on Equity for this stock inclined to 21.59, with Return on Assets sitting at 19.35. When it comes to the capital structure of this company, Exelixis Inc. [EXEL] has a Total Debt to Total Equity ratio set at 3.01. Additionally, EXEL Total Debt to Total Capital is recorded at 2.92, with Total Debt to Total Assets ending up at 2.68. Long-Term Debt to Equity for the company is recorded at 2.85, with the Long-Term Debt to Total Capital now at 2.76.
Reflecting on the efficiency of the workforce at the company, Exelixis Inc. [EXEL] managed to generate an average of $520,279 per employee. Receivables Turnover for the company is 6.47 with a Total Asset Turnover recorded at a value of 0.58.Exelixis Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.90 and a Current Ratio set at 7.00.
Exelixis Inc. [EXEL]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Exelixis Inc. posted 0.22/share EPS, while the average EPS was predicted by analysts to be reported at 0.16/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 37.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EXEL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Exelixis Inc. go to 46.00%.
An analysis of insider ownership at Exelixis Inc. [EXEL]
There are presently around $5,305 million, or 85.00% of EXEL stock, in the hands of institutional investors. The top three institutional holders of EXEL stocks are: BLACKROCK INC. with ownership of 30,626,404, which is approximately -2.778% of the company’s market cap and around 1.10% of the total institutional ownership; VANGUARD GROUP INC, holding 27,790,831 shares of the stock with an approximate value of $571.38 million in EXEL stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $466.0 million in EXEL stock with ownership of nearly -1.483% of the company’s market capitalization.
Positions in Exelixis Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 159 institutional holders increased their position in Exelixis Inc. [NASDAQ:EXEL] by around 21,414,172 shares. Additionally, 194 investors decreased positions by around 18,232,338 shares, while 67 investors held positions by with 218,364,487 shares. The mentioned changes placed institutional holdings at 258,010,997 shares, according to the latest SEC report filing. EXEL stock had 46 new institutional investments in for a total of 5,162,940 shares, while 49 institutional investors sold positions of 2,605,343 shares during the same period.